Omalizumab safety in pregnancy

Affiliations

¹ Institute for Drug Research, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. Electronic address: francescal@ekmd.huji.ac.il.
² Department of Obstetrics and Gynecology, Hadassah Hebrew University Hospital, Jerusalem, Israel.

Editorial

Francesca Levi-Schaffer et al. J Allergy Clin Immunol. 2020 Feb.

. 2020 Feb;145(2):481-483.

doi: 10.1016/j.jaci.2019.11.018. Epub 2019 Nov 26.

¹ Institute for Drug Research, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. Electronic address: francescal@ekmd.huji.ac.il.
² Department of Obstetrics and Gynecology, Hadassah Hebrew University Hospital, Jerusalem, Israel.

No abstract available

Keywords: Omalizumab; drug safety; fetal malformations; placental transfer; pregnancy; preterm delivery; thrombocytopenia.

Comment on

Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort.
Namazy JA, Blais L, Andrews EB, Scheuerle AE, Cabana MD, Thorp JM, Umetsu DT, Veith JH, Sun D, Kaufman DG, Covington DL, Mukhopadhyay S, Fogel RB, Lopez-Leon S, Spain CV. Namazy JA, et al. J Allergy Clin Immunol. 2020 Feb;145(2):528-536.e1. doi: 10.1016/j.jaci.2019.05.019. Epub 2019 May 27. J Allergy Clin Immunol. 2020. PMID: 31145939